Journal of Innovative Clinical Trials and Case Reports

Abstract

Background: Palm-derived tocotrienols have plausible antioxidant and anti-inflammatory activities, yet an early randomised trial found no statistically significant scar-prevention benefit for a 5% topical formulation.

Objective: To explain the apparent translational discordance and establish a clinically testable research agenda for postoperative incisional scars.

Methods: A critical qualitative literature review integrated purposively selected journal studies from 2020–2026 with the landmark 2011 trial. Evidence was organised thematically across scar biology, formulation science, comparative treatments, outcome instruments and trial design.

Results: The neutral clinical signal remains the most directly relevant efficacy evidence. Laboratory wound closure, animal regeneration, topical delivery feasibility and mechanistic fibrosis research are informative but indirect. Unmeasured dermal exposure, molecular target engagement, timing after epithelialisation, wound tension and scar-risk heterogeneity hinder causal interpretation. Modern scar measurement increasingly combines patient-reported measures with objective assessments; comparator studies illustrate both possibilities and methodological limits.

Discussion: A staged formulation–exposure–target engagement–clinical outcome model can prevent promising mechanisms from being mistaken for proven patient benefit.

Conclusions: Routine preventive use of tocotrienol cream cannot be justified on current evidence. Before another definitive trial, botanical identity, formulation stability, tissue exposure, early human safety and patient-important endpoints should be prospectively validated.